新闻资讯
收支信息
  • 收入总额:27103501.49元
  • 支出总额:23122739.73元
  • 爱心人次:2242次
穿山甲退出中药有重大进展:点赞中医临综考研大纲
2019/7/10 20:41:00 本站中国绿发会

7月10日,中国生物多样性保护与绿色发展基金会(简称“绿会”)工作人员在微博上看到一则令人欣慰的消息:2020年中医临综考研大纲相较于2019年作出了些微改动,删除了中药学活血化瘀药中的穿山甲一项。绿会工作人员立刻到网上对该消息进行查证,发现消息属实。大纲中虽仍未删除以穿山甲为原料的理血剂“复元活血汤”,但与从前相比,已是巨大的进步。绿会穿山甲保护工作者们为此点赞。


微信图片_20190710193702.png

绿会从2015年起,一直致力于反对将穿山甲入药的工作。穿山甲科共有三属8种,现已全部濒危,野外种群数量十分稀少。在我国,穿山甲是二级保护动物,在国际上也已列入《世界自然保护联盟》(IUCN)2014年濒危物种红色名录。2016年,穿山甲被列入《华盛顿公约》CITES 附录Ⅰ级保护动物禁止全球贸易。2019年,绿会宣布中国大陆的穿山甲本土物种中华穿山甲,在中国大陆功能性灭绝,引发了热烈的讨论。由于非法贸易猖獗,穿山甲数量相比上世纪六七十年代,已下降了90%以上,而致使非法贸易屡禁不止的重要因素,正是穿山甲庞大的药用市场。


传统中医认为,穿山甲鳞片是名贵的药材,可以活血化瘀、下乳消肿、治疗乳汁不下、闭经不通、风湿痹痛、筋骨拘挛、痈肿初起等病症。然而,中药典籍中可以药用的穿山甲,实际上单指中华穿山甲,而前文提到,中华穿山甲在野外的数量已经十分稀少了,根本无法支撑庞大的市场需求。那么市场上大量的穿山甲药材又是从何而来?答案指向了非法贸易。


现今市场上的穿山甲产品,大多源自于非洲穿山甲的非法贸易。非洲穿山甲和中华穿山甲为不同种属,将其用药是为无稽之谈。而关于穿山甲鳞片的药用价值,早有相关中药研究方面的论文证明其成分主要是角质,并无太大药用功能。中国古代医学著作《名医别录》和《神农本草经》中皆将穿山甲归类于为下品药。《药性论》中,甚至有“(穿山甲)药性大毒”的记载。


2019年,绿会在两会提案:“参照《国务院关于禁止犀牛角和虎骨贸易的通知》(国发[1993]39号)文件,取消穿山甲药用标准,将穿山甲从药典中删除,今后不得再用甲片制药。对已生产出的含穿山甲成分的中药成方制剂进行查封,禁止出售。对库存甲片予以公开销毁,彻底消除流入市场的可能。同时停止核发穿山甲人工繁育许可,整顿检查现有穿山甲人工养殖场,建立科学完善的穿山甲保护性繁育的管理制度,严格饲养标准,精细谱系管理,保障基因多样性的最大化,服务于放归和野外研究。对不达标的、追求商业利用的养殖场要坚决予以取缔。”


穿山甲从中医临综考研大纲中删除,不仅体现了中医严谨的科学性、跟随时代的进步性,也是令穿山甲退出中药市场的重大进展,更是我国生物多样性保护工作者和穿山甲命运关注者为保护濒危物种不停努力的结果。


文/Zine 审/Sophia 编/Angel



Pangolin Withdrawal from Chinese Medicine Has Made Significant Progress: Praise Expurgation of Pangolin from the Chinese Medicine Postgraduate Examination Outline


Today, staffs of the China Biodiversity Conservation and Green Development Foundation saw a gratifying news on Weibo: In 2020, the outline of the Chinese Medicine Postgraduate Examination was slightly modified compared to 2019: the Chinese medicine part removed pangolin scales which is used as medicine to promote blood circulation. The staff immediately went online to verify the news and they were happy to see was it was true.  Although the physiotherapy agent "Recovery Blood Soup", which uses pangolin as raw material, has not been deleted in the syllabus, it is a huge improvement compared with the past. CBCGDF pangolin protectors still feel cheerful about this.


Since 2015, CBCGDF has been working against the use of pangolins for medicine. The pangolin family has three genera and eight species, all of which are now endangered, and the number of wild populations is very rare. In China, pangolins are secondary class protected animals and have been listed in the International Union for the Conservation of Nature (IUCN) 2014 Red List of Endangered Species. In 2016, pangolins were included in the Washington Convention CITES Appendix I protected animals forbidden global trade.  In 2019, CBCGDF announced the Chinese pangolin, a native species of pangolin in mainland China, whose functional extinction in mainland China has sparked heated discussions. Due to the illicit trade, the number of pangolins has dropped by more than 90% compared with the 1960s and 1970s, and the important factor that has led to the ban on illegal trade is the huge medicinal market of pangolins.


Traditional Chinese medicine believes that pangolin scales are valuable medicinal materials, which can activate blood circulation, reducing swelling, treating breast milk, amenorrhea, rheumatism and phlegm. However, the pangolin in the Chinese medicine classics actually refers to the Chinese pangolin, not others. As mentioned above, the number of Chinese pangolins in the wild is very scarce, and it is impossible to support the huge market demand.  So where does the large amount of pangolin medicinal materials come from? The answer points to illegal trade.


Most of the pangolin products on the market today are derived from the illegal trade of pangolins in Africa. African pangolins and Chinese pangolins belong to different species, and their medical use is of course unreasonable. As for the medicinal value of pangolin scales, there have been some papers on the research of traditional Chinese medicine prove that the ingredients are mainly keratin and have no medicinal function. The ancient Chinese medical books "Medical Doctors" and "Shen Nong's Herbal Classics" all classify pangolins as the lower medicine. In the "Pharmaceutical Theory", there is even a record of "(Pangolin) drug-like toxicity".


In 2019, CBCGDF proposed in the National People’s Congress and the Chinese Political Consultative Conference (NPC and CPPCC): "Refer to the "Notice of the State Council on Prohibiting the Trade of Rhinoceros Horn and Tiger Bone" (Guo Fa [1993] No. 39), cancel the medicinal standard of pangolin, and remove the pangolin from the Pharmacopoeia.  Then use the tablet pharmacy. The traditional Chinese medicine preparations containing the pangolin components have been sealed up and prohibited from being sold. The stocks should be publicly destroyed, and the possibility of entering the market is completely eliminated. At the same time, the artificial breeding license is stopped, and the inspection is rectified. Existing pangolin artificial farms, establish a scientific and perfect management system for protective breeding of pangolins, strict breeding standards, fine lineage management, guarantee the maximization of genetic diversity, serve the release and field research. "


The Expurgation of pangolin from the Outline of the Chinese Medicine Postgraduate Examination not only reflects the rigorous scientific trait of Chinese medicine, but also the progress of the times. It is also a major progress in the withdrawal of pangolins from the Chinese medicine market, huge achievement of a concern of China's biodiversity conservation protectors.


【推 荐 阅 读】

穿山甲:误读千载,我不是药神!也许是“毒药”

林腾蛟代表:加大穿山甲、熊胆等濒危野生动物药替代品研发|绿会提案建议会

小学教参书将穿山甲列为药品极为不当,绿会律师函致出版社要求整改获媒体广泛报道

穿山甲数量急剧下降,濒危物种保护与中医药用该如何协调?

香港中医教授:勿迷信穿山甲鳞片夸大其词的药效,有多种替代品

非中华穿山甲不可入药,绿会在第二届中医药文化大会新闻发布会上说

穿山甲日,专家呼吁停止入药和人工养殖

美国杜克大学志愿者采访绿会秘书长穿山甲入药问题

香港民建联(DAB)全国两会建议停止穿山甲入药,绿会隔空喊话:穿山甲化石研究需要各方支持

2019两会 | 民建聊加快推进穿山甲药行业转型升级的建议

应立法禁止穿山甲用于催乳通乳药制品 |“穿山甲妈妈”2019两会建议

你用的穿山甲药有问题!国家药品监督管理局公布14起穿山甲药不合规

穿山甲或将从中国药典删除,绿会取得阶段性成果 |《中国药典》2020年版四部通则增修订内容

建议取消穿山甲鳞片入药,保护唯一披鳞甲的哺乳动物 | 绿会2019两会提案建议